Literature DB >> 21694617

Switching antidepressant class does not improve response or remission in treatment-resistant depression.

Daniel Souery1, Alessandro Serretti, Raffaella Calati, Pierre Oswald, Isabelle Massat, Anastasios Konstantinidis, Sylvie Linotte, Joseph Bollen, Koen Demyttenaere, Siegfried Kasper, Yves Lecrubier, Stuart Montgomery, Joseph Zohar, Julien Mendlewicz.   

Abstract

OBJECTIVE: The management of treatment-resistant depression is a much debated issue. In particular, the evidence supporting the commonly suggested sequential use of antidepressants from 2 different pharmacological classes is weak. This retrospective study was undertaken to investigate whether there is a better response in nonresponders switched to a different class of antidepressants (across-class) compared with nonresponders switched to an antidepressant from the same class (within-class).
METHODS: Three hundred forty patients with primary major depressive disorder were recruited in the context of a European multicenter project. Subjects whose current depressive episode had failed to respond to a first antidepressant trial of adequate dose and duration were included.
RESULTS: There was no significant difference in response or remission rates between the across-class and within-class groups after controlling for possible confounders.
CONCLUSIONS: In depressed nonresponders to a previous antidepressant treatment, switching to a different class of antidepressants was not associated with a better response or remission rate.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21694617     DOI: 10.1097/JCP.0b013e3182228619

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  24 in total

1.  Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.

Authors:  Chiara Fabbri; Concetta Crisafulli; Raffaella Calati; Diego Albani; Gianluigi Forloni; Marco Calabrò; Rosalba Martines; Siegfried Kasper; Joseph Zohar; Alzbeta Juven-Wetzler; Daniel Souery; Stuart Montgomery; Julien Mendlewicz; Alessandro Serretti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-04       Impact factor: 5.270

2.  Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder.

Authors:  Alessandro Serretti; Alberto Chiesa; Raffaella Calati; Sylvie Linotte; Othman Sentissi; Konstantinos Papageorgiou; Siegfried Kasper; Joseph Zohar; Diana De Ronchi; Julien Mendlewicz; Daniela Amital; Stuart Montgomery; Daniel Souery
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-05-09       Impact factor: 5.270

3.  Upregulation of neuronal kynurenine 3-monooxygenase mediates depression-like behavior in a mouse model of neuropathic pain.

Authors:  Geoffroy Laumet; Wenjun Zhou; Robert Dantzer; Jules D Edralin; XiaoJiao Huo; David P Budac; Jason C O'Connor; Anna W Lee; Cobi J Heijnen; Annemieke Kavelaars
Journal:  Brain Behav Immun       Date:  2017-07-11       Impact factor: 7.217

Review 4.  Switching and stopping antidepressants.

Authors:  Nicholas Keks; Judy Hope; Simone Keogh
Journal:  Aust Prescr       Date:  2016-06-01

5.  Identifying the Common Genetic Basis of Antidepressant Response.

Authors:  Oliver Pain; Karen Hodgson; Vassily Trubetskoy; Stephan Ripke; Victoria S Marshe; Mark J Adams; Enda M Byrne; Adrian I Campos; Tania Carrillo-Roa; Annamaria Cattaneo; Thomas D Als; Daniel Souery; Mojca Z Dernovsek; Chiara Fabbri; Caroline Hayward; Neven Henigsberg; Joanna Hauser; James L Kennedy; Eric J Lenze; Glyn Lewis; Daniel J Müller; Nicholas G Martin; Benoit H Mulsant; Ole Mors; Nader Perroud; David J Porteous; Miguel E Rentería; Charles F Reynolds; Marcella Rietschel; Rudolf Uher; Eleanor M Wigmore; Wolfgang Maier; Naomi R Wray; Katherine J Aitchison; Volker Arolt; Bernhard T Baune; Joanna M Biernacka; Guido Bondolfi; Katharina Domschke; Masaki Kato; Qingqin S Li; Yu-Li Liu; Alessandro Serretti; Shih-Jen Tsai; Gustavo Turecki; Richard Weinshilboum; Andrew M McIntosh; Cathryn M Lewis
Journal:  Biol Psychiatry Glob Open Sci       Date:  2022-04

6.  Novel antidepressant effects of Paeonol alleviate neuronal injury with concomitant alterations in BDNF, Rac1 and RhoA levels in chronic unpredictable mild stress rats.

Authors:  Xiu-Ling Zhu; Jing-Jing Chen; Fei Han; Chuan Pan; Ting-Ting Zhuang; Ya-Fei Cai; Ya-Ping Lu
Journal:  Psychopharmacology (Berl)       Date:  2018-05-12       Impact factor: 4.530

7.  Treatment-resistant depression: therapeutic trends, challenges, and future directions.

Authors:  Khalid Saad Al-Harbi
Journal:  Patient Prefer Adherence       Date:  2012-05-01       Impact factor: 2.711

8.  Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample.

Authors:  Leonardo Zaninotto; Daniel Souery; Raffaella Calati; Giovanni Camardese; Luigi Janiri; Stuart Montgomery; Siegfried Kasper; Joseph Zohar; Diana De Ronchi; Julien Mendlewicz; Alessandro Serretti
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-04-30       Impact factor: 2.582

9.  Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care.

Authors:  Antoni Sicras-Mainar; Jorge Maurino; Luis Cordero; Milagrosa Blanca-Tamayo; Ruth Navarro-Artieda
Journal:  Ann Gen Psychiatry       Date:  2012-08-03       Impact factor: 3.455

10.  Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment.

Authors:  Mauro Garcia-Toro; Esteban Medina; Jaime L Galan; Miguel A Gonzalez; Jorge Maurino
Journal:  BMC Psychiatry       Date:  2012-09-18       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.